Welltower
WELL
$232.12
-0.76%
Welltower is a real estate investment trust (REIT) that owns a diversified healthcare portfolio of approximately 2,800 properties across senior housing, medical office, and skilled nursing/post-acute care sectors, with operations in the U.S., Canada, and the U.K. As one of the largest healthcare REITs globally, it distinguishes itself through its scale, geographic diversification, and focus on high-barrier-to-entry markets. The current investor narrative centers on the company's strong operating momentum, driven by robust senior housing demand and margin expansion, as well as the potential for further growth from recent acquisitions and favorable demographic tailwinds. Recent news highlights the broader real estate rebound narrative, with rate cuts potentially benefiting the sector, while Welltower's own financial results have shown accelerating revenue growth and improving profitability.…
WELL
Welltower
$232.12
Related headlines
Investment Opinion: Should I buy WELL Today?
Rating: Buy. Thesis: Welltower's accelerating revenue growth, expanding margins, and strong balance sheet position it to benefit from favorable demographic trends, making it a compelling long-term investment despite a high valuation. The analyst consensus is bullish, with an implied average target of ~$365 based on forward P/E of 70.3x and estimated EPS of $5.20.
Supporting Evidence: Revenue grew 41.2% YoY in Q4 2025, gross margin expanded to 38.3%, free cash flow is $2.85B TTM, and the forward P/E of 70.3x implies significant earnings growth. The debt-to-equity ratio of 0.51 is low, and the current ratio of 5.34 indicates strong liquidity. The stock's 56.6% one-year gain reflects strong momentum, and analyst estimates suggest further upside.
Risks & Conditions: The biggest risks are interest rate sensitivity and the high trailing P/E. If rates rise sharply or revenue growth decelerates below 20%, the stock could correct. This Buy would downgrade to Hold if the forward P/E exceeds 80x or if EBITDA remains negative. The stock appears fairly valued relative to its growth trajectory but overvalued on trailing earnings; however, the forward metrics justify the premium.
Sign up to view all
WELL 12-Month Price Forecast
Welltower's strong fundamental momentum and favorable demographics support a bullish stance, but the high valuation and interest rate sensitivity warrant caution. The base case of 20-25% revenue growth and gradual margin expansion is most likely, with a target range of $240-$280. The bull case of 30%+ growth and rate cuts could drive the stock to $280-$320, while the bear case of deceleration and higher rates could pull it to $180-$220. The stance would upgrade to high confidence if revenue growth sustains above 30% and margins continue to expand, and downgrade to neutral if growth falls below 20% or interest rates rise significantly.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Welltower's 12-month outlook, with a consensus price target around $301.76 and implied upside of +30.0% versus the current price.
Average Target
$301.76
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$186 - $302
Analyst target range
Welltower is covered by 5 analysts, with a consensus recommendation that leans bullish. The average target price is not explicitly provided, but based on the estimated EPS average of $5.20 and the forward P/E of 70.3x, the implied target price is approximately $365. However, this is a rough calculation. The distribution of ratings is not given, but the institutional ratings show a mix of Overweight, Sector Outperform, and In Line ratings, indicating a generally positive sentiment. The implied upside from the current price of $236.06 to the average target (if we use the forward P/E implied target) would be about +55%, which is substantial. The high target, based on the high EPS estimate of $5.66 and a similar multiple, could be around $398, while the low target, based on the low EPS estimate of $4.92, would be around $346. The wide range of EPS estimates ($4.92 to $5.66) suggests some uncertainty about the pace of earnings growth. Recent analyst actions have been mostly neutral to positive, with Wells Fargo downgrading from Overweight to Equal Weight in October 2024, but other firms like Deutsche Bank and Morgan Stanley maintaining Buy/Overweight ratings. The overall sentiment is cautiously optimistic, with analysts expecting continued growth but acknowledging potential headwinds from interest rates and property market conditions.
Bulls vs Bears: WELL Investment Factors
Welltower presents a compelling growth story with accelerating revenue, expanding margins, and strong demographic tailwinds. The bull case is supported by 41.2% revenue growth, a solid balance sheet, and favorable long-term demand. However, the bear case highlights an extremely high trailing P/E of 131.6x, negative EBITDA in the latest quarter, and sensitivity to interest rates. Currently, the bull case has stronger evidence given the fundamental momentum, but the key tension is whether the market's high growth expectations are realistic. If revenue growth decelerates or interest rates rise, the stock could face significant multiple compression. The single most important factor is the sustainability of 40%+ revenue growth and margin expansion.
Bullish
- Revenue Growth Accelerating Strongly: Q4 2025 revenue grew 41.2% YoY to $3.13B, up from 22.2% growth in Q4 2024, driven by senior housing demand and acquisitions. This acceleration signals strong operational momentum and market share gains.
- Margin Expansion Improving Profitability: Gross margin expanded to 38.3% in Q4 2025 from 36.5% a year earlier, reflecting operating leverage. Underlying operating margins are improving despite one-time charges that depressed net income.
- Strong Balance Sheet with Low Leverage: Debt-to-equity ratio of 0.51 and current ratio of 5.34 indicate ample liquidity and manageable financial risk. Free cash flow of $2.85B TTM provides internal funding for growth and dividends.
- Favorable Demographic Tailwinds: Aging population in the U.S., Canada, and U.K. drives long-term demand for senior housing and healthcare properties. Welltower's 2,800-property portfolio is well-positioned to benefit from this secular trend.
Bearish
- Extremely High Trailing P/E Multiple: Trailing P/E of 131.6x is elevated even for a REIT, implying the market is pricing in aggressive future earnings growth. Any disappointment could lead to multiple compression.
- Negative EBITDA in Q4 2025: EBITDA was -$459M in Q4 2025 due to large non-cash charges, raising concerns about earnings quality. While likely one-time, it adds volatility to reported earnings.
- Interest Rate Sensitivity: As a REIT, Welltower is sensitive to interest rates. Higher-for-longer rates could increase borrowing costs and cap rate expansion, pressuring property values and earnings.
- Modest ROE and Net Margin: ROE of 2.2% and net margin of 3.1% in Q4 2025 are low, though improving. The company generates significant depreciation charges that depress net income, but underlying cash flow is stronger.
WELL Technical Analysis
Welltower is in a sustained uptrend, with the stock price up 56.6% over the past year, significantly outperforming the S&P 500's 19.1% gain. The current price of $236.06 sits at the very top of its 52-week range (52-week high: $236.06, low: $150.53), representing 100% of the range. This positioning near the highs indicates strong momentum and bullish sentiment, though it also suggests the stock may be overextended in the short term. The 1-year price change of 56.6% reflects a powerful trend driven by fundamental improvements and sector tailwinds. Short-term momentum is accelerating, with the stock up 20.8% in the past month and 16.7% over the past three months. The 1-month gain of 20.8% is particularly strong and has outpaced the S&P 500's 1-month decline of 1.25%, resulting in a relative strength of 22.1% over that period. This acceleration in momentum aligns with the longer-term uptrend, suggesting no divergence; rather, the stock is gaining speed as it approaches new highs. The 3-month change of 16.7% is also robust, confirming the bullish trend. Key support lies at the 52-week low of $150.53, while resistance is at the recent high of $236.06, which the stock is currently testing. A breakout above $236.06 would signal a continuation of the uptrend and open the door to further gains, while a failure to hold above this level could lead to a pullback toward the $220 area. The stock's beta of 0.763 indicates it is less volatile than the overall market, meaning it tends to move less than the S&P 500. This lower beta suggests that Welltower's recent strong performance is driven by company-specific factors rather than broad market moves, and it also implies that the stock may offer a smoother ride for investors compared to higher-beta names.
Beta
0.76
0.76x market volatility
Max Drawdown
-12.6%
Largest decline past year
52-Week Range
$151-$239
Price range past year
Annual Return
+52.5%
Cumulative gain past year
| Period | WELL Return | S&P 500 |
|---|---|---|
| 1m | +12.3% | +2.0% |
| 3m | +11.8% | +10.6% |
| 6m | +24.7% | +8.3% |
| 1y | +52.5% | +20.4% |
| ytd | +24.2% | +10.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
WELL Fundamental Analysis
Welltower's revenue trajectory is strongly accelerating, with Q4 2025 revenue of $3.13 billion representing a 41.2% year-over-year growth rate, up from 22.2% growth in Q4 2024. This acceleration is driven by robust senior housing demand and contributions from recent acquisitions. The company's revenue has grown sequentially from $2.39 billion in Q1 2025 to $3.13 billion in Q4 2025, reflecting a consistent upward trend. The management service segment, which generated $2.06 billion in revenue, is a key driver, though the overall growth is broad-based across property types. This strong revenue growth supports the investment case, as it indicates the company is successfully capitalizing on favorable demographic trends and executing its acquisition strategy. Profitability is improving, with net income of $96.4 million in Q4 2025, up from $120.0 million in Q4 2024, despite a significant increase in depreciation and amortization. Gross margin has expanded to 38.3% in Q4 2025 from 36.5% in Q4 2024, reflecting operating leverage and improved property-level performance. However, the company reported negative EBITDA of -$459 million in Q4 2025 due to large non-cash charges, but on a trailing twelve-month basis, EBITDA is positive. The net margin of 3.1% in Q4 2025 is lower than the 5.4% in Q4 2024, but this is due to one-time items; the underlying operating margin is improving. The company's balance sheet is solid, with a debt-to-equity ratio of 0.51 and a current ratio of 5.34, indicating ample liquidity. Free cash flow for the trailing twelve months is $2.85 billion, providing strong internal funding for growth. The ROE of 2.2% is modest but improving, and the company's FCF yield of approximately 2.3% (based on market cap of $123.5 billion) is reasonable for a REIT. The low debt-to-equity ratio suggests financial risk is manageable, and the company has significant capacity to fund acquisitions and dividends.
Quarterly Revenue
$3.1B
2025-12
Revenue YoY Growth
+41.24%
YoY Comparison
Gross Margin
38.30%
Latest Quarter
Free Cash Flow
$2.8B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is WELL Overvalued?
Since Welltower has positive net income, we lead with the P/E ratio. The trailing P/E is 131.6x, while the forward P/E is 70.3x, implying that the market expects significant earnings growth in the coming year. The wide gap between trailing and forward P/E suggests that the market is pricing in a substantial earnings recovery, which aligns with the company's improving profitability trends. The P/E of 131.6x is extremely high, but this is typical for REITs with high depreciation charges that depress net income; a more appropriate metric is P/FFO, but that data is not provided. Compared to the industry average (not provided), Welltower's P/E is likely at a premium given its growth profile. The PS ratio of 11.6x is also elevated, reflecting the premium the market places on its revenue growth and market position. The EV/EBITDA of 60.5x is high, but again, this is influenced by the negative EBITDA in the most recent quarter. The PEG ratio of -12.2x is negative due to negative earnings growth expectations, but this is misleading as earnings are expected to rebound. Historically, Welltower's trailing P/E has ranged from around 43x to 332x over the past few years, with the current 131.6x near the middle of that range. The P/B ratio of 2.93x is above the historical low of 1.56x in 2022 but below the high of 3.09x in 2025, suggesting the stock is fairly valued relative to its book value. The current valuation reflects optimism about the company's growth trajectory, but it is not at extreme levels compared to its own history.
PE
131.6x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -2125x~344x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
60.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Welltower's high trailing P/E of 131.6x implies aggressive growth expectations that may not materialize. The negative EBITDA of -$459M in Q4 2025, while partly due to non-cash charges, adds earnings volatility. The net margin of 3.1% is thin, and ROE of 2.2% is modest, though improving. The company's reliance on acquisitions for growth could lead to integration risks and potential overpayment for assets. Free cash flow of $2.85B TTM provides a cushion, but any slowdown in revenue growth could pressure the valuation.
Market & Competitive Risks: The stock's beta of 0.763 suggests lower market correlation, but as a REIT, it is sensitive to interest rate movements. Higher rates could increase cap rates and reduce property values. The healthcare REIT sector is competitive, with players like Ventas and Healthpeak vying for assets. Regulatory changes in healthcare reimbursement could impact tenant demand. Recent news highlights a potential real estate rebound from rate cuts, but if cuts are delayed, the sector could underperform.
Worst-Case Scenario: A sharp rise in interest rates combined with a slowdown in senior housing occupancy could lead to earnings misses and multiple compression. In this scenario, the stock could fall to its 52-week low of $150.53, representing a -36% decline from the current price of $236.06. This would imply a P/E contraction to around 85x trailing, still elevated but reflecting lower growth expectations.
FAQ
The key risks are: 1) Interest rate sensitivity – as a REIT, higher rates could increase cap rates and lower property values; 2) Valuation risk – trailing P/E of 131.6x leaves little room for error; 3) Earnings volatility – negative EBITDA in Q4 2025 highlights potential for one-time charges; 4) Competitive risk – other healthcare REITs like Ventas compete for acquisitions. The most severe risk is a sharp rate hike, which could drive the stock down 36% to the 52-week low of $150.53.
The 12-month forecast is cautiously bullish. The base case (50% probability) sees revenue growth moderating to 20-25%, with the stock trading in a $240-$280 range. The bull case (30% probability) of sustained 30%+ growth and rate cuts could push the stock to $280-$320. The bear case (20% probability) of deceleration and higher rates could pull it to $180-$220. The most likely scenario is the base case, driven by continued but moderating growth. Analyst estimates imply an average target of ~$365 based on forward P/E, but this seems optimistic given current multiples.
Welltower appears overvalued on trailing earnings (P/E 131.6x) but fairly valued on forward earnings (P/E 70.3x) given expected growth. The PS ratio of 11.6x is elevated, reflecting a premium for its revenue growth. Compared to its historical P/E range of 43x-332x, the current 131.6x is near the middle, suggesting it is not at extreme levels. The market is pricing in strong earnings recovery, which is plausible given the 41.2% revenue growth. Overall, the stock is fairly valued relative to its growth trajectory but expensive on current earnings.
Welltower is a good buy for investors with a long-term horizon who can tolerate valuation risk. The stock offers strong revenue growth (41.2% YoY) and improving margins, with a forward P/E of 70.3x implying significant earnings growth. Analyst targets suggest ~55% upside from current levels, but the trailing P/E of 131.6x is high. The biggest downside risk is interest rate sensitivity, which could compress multiples. For growth-oriented investors, the risk/reward is favorable given demographic tailwinds, but value investors may find the valuation stretched. It is best suited as a core holding in a diversified portfolio.
Welltower is best suited for long-term investment (3-5 years) due to its secular growth drivers in senior housing and healthcare. The stock's beta of 0.763 indicates lower volatility than the market, making it a relatively stable long-term hold. The 1.52% dividend yield provides some income, though it is not a high-yield play. Short-term trading is riskier given the stock is near its 52-week high and could be volatile on interest rate news. A minimum holding period of 3 years is recommended to ride out potential rate cycles and allow earnings growth to catch up with the valuation.